Pregled bibliografske jedinice broj: 889443
RUSSELL - SILVER SYNDROME - clinical and molecular perspective
RUSSELL - SILVER SYNDROME - clinical and molecular perspective // 10th ISABS Conference Program and Abstracts / Primorac Dragan i sur. (ur.).
Zagreb: Internationa Society for Applied Biological Sciences (ISABS), 2017. str. 306-306 (poster, međunarodna recenzija, sažetak, znanstveni)
CROSBI ID: 889443 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
RUSSELL - SILVER SYNDROME - clinical and molecular perspective
Autori
Kristina Crkvenac Gornik, Ivana Tonkovic Durisevic, Sanda Huljev Frkovic, Iva Kolombo, Ela Brgodac, Vjekoslav Krzelj, Bernarda Lozic.
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Izvornik
10th ISABS Conference Program and Abstracts
/ Primorac Dragan i sur. - Zagreb : Internationa Society for Applied Biological Sciences (ISABS), 2017, 306-306
ISBN
978-953-57695-2-1
Skup
10th ISABS Conference
Mjesto i datum
Dubrovnik, Hrvatska, 19.06.2017. - 24.06.2017
Vrsta sudjelovanja
Poster
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
Russell - Silver syndrome, growth hormone therapy
Sažetak
Russell - Silver syndrome (RSS) is a rare genetic disorder characterized by intrauterine and postnatal growth retardation with normal head circumference, specific facial dysmorphia, fifth finger clinodactyly and asymmetry of the face, body and/or limbs. It is a genetically heterogeneous condition that is mostly associated with genetic and epigenetic alterations at chromosome 11p15.5 region and chromosome 7. Most common alteration is 11p15.5 hypomethylation of the paternal imprinting center 1 detected in 30%-50% of individuals with RSS. Growth failure is the primary abnormality. The average adult height of males is 151, 2 cm (-7.8 SD) and that of females is 139.9 cm (-9 SD), if not treated with growth hormone (GH). Children with RSS have benefited from GH supplementation even in the absence of GH deficiency so the GH therapy should be considered in every child with RSS who has not manifested adequate catch-up growth by age 2 years. We present three children with typical clinical characteristics of RSS whose diagnoses were genetically confirmed with the MS-MLPA (methylation specific multiplex ligation- dependent probe amplification). The girl underwent a growth hormone therapy at age 2 years and two boys are yet to be. Many still ongoing studies of children with RSS who have received GH are difficult to interpret because of lack of etiologic data included in these studies, given the known genetic heterogeneity of the RSS. So, it will be important to look at the long-term effects of growth hormone therapy in our patients, especially with respect to influence on final adult height.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Ustanove:
Medicinski fakultet, Zagreb,
KBC Split,
Klinički bolnički centar Zagreb,
Medicinski fakultet, Split
Profili:
Kristina Crkvenac
(autor)
Bernarda Lozić
(autor)
Ivana Tonković
(autor)
Vjekoslav Krželj
(autor)